William Phd Link Sells 12,500 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Key Points

• Director William Phd Link sold 12,500 Tarsus Pharmaceuticals shares at an average price of $78.38, generating approximately $979,750. The sale, conducted under a Rule 10b5-1 plan, reduced his holdings by 11.68% to 94,487 shares.
• TARS shares rose 1.8% to $79.06, with the company valued at approximately $3.47 billion. Its stock remains below its 12-month high of $91.53 but above its 50-day and 200-day moving averages.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $94.00. However, Tarsus recently missed quarterly EPS expectations despite reporting revenue above estimates.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) Director William Phd Link sold 12,500 shares of the company's stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $78.38, for a total value of $979,750.00. Following the sale, the director owned 94,487 shares of the company's stock, valued at $7,405,891.06. This trade represents a 11.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tarsus Pharmaceuticals Stock Up 1.8%

TARS stock traded up $1.42 during trading on Thursday, reaching $79.06. 426,958 shares of the company traded hands, compared to its average volume of 748,133. The business has a 50 day simple moving average of $68.73 and a 200 day simple moving average of $66.71. Tarsus Pharmaceuticals, Inc. has a 12 month low of $51.57 and a 12 month high of $91.53. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.17 and a current ratio of 3.20. The company has a market capitalization of $3.47 billion, a price-to-earnings ratio of -72.53 and a beta of 0.54.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%.The firm had revenue of $173.91 million during the quarter, compared to the consensus estimate of $169.65 million. On average, equities research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -2.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Rockefeller Capital Management L.P. increased its holdings in Tarsus Pharmaceuticals by 15.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company's stock valued at $105,000 after buying an additional 172 shares in the last quarter. Parallel Advisors LLC raised its position in shares of Tarsus Pharmaceuticals by 139.2% in the first quarter. Parallel Advisors LLC now owns 500 shares of the company's stock worth $35,000 after acquiring an additional 291 shares during the period. Strs Ohio boosted its stake in shares of Tarsus Pharmaceuticals by 4.8% during the 1st quarter. Strs Ohio now owns 8,800 shares of the company's stock worth $617,000 after acquiring an additional 400 shares in the last quarter. Swiss National Bank boosted its stake in shares of Tarsus Pharmaceuticals by 0.8% during the 1st quarter. Swiss National Bank now owns 62,933 shares of the company's stock worth $4,415,000 after acquiring an additional 500 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its position in shares of Tarsus Pharmaceuticals by 367.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 710 shares of the company's stock valued at $50,000 after acquiring an additional 558 shares during the period. 90.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

TARS has been the subject of a number of analyst reports. Guggenheim decreased their target price on shares of Tarsus Pharmaceuticals from $90.00 to $89.00 and set a "buy" rating for the company in a research report on Tuesday, July 21st. Barclays assumed coverage on shares of Tarsus Pharmaceuticals in a report on Wednesday. They issued an "overweight" rating and a $110.00 price target on the stock. Wall Street Zen lowered Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. Oppenheimer raised their price objective on Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 12th. Finally, Mizuho lowered their price objective on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an "outperform" rating for the company in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $94.00.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye conditions with significant unmet medical needs. The company's lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, a prescription eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, a common eyelid disorder associated with an infestation of Demodex mites.

XDEMVY is designed to target and eliminate Demodex mites, addressing an underlying cause of the disease rather than only managing its symptoms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.